Stem Bark Extract from *Alstonia boonei* attenuates Cholesterol, Triglyceride and Oxidative Damage via Low Immunohistochemical Expression in Small Intestinal Tract of Male Rats

Akintunde Jacob Kehinde1*, Ajiboye John Adebayo2, Soyinka O Oluwadamilola2 and Adeyemi A Arinola2

1Toxicology and Safety Unit, Department of Environmental Health Sciences, College of Medicine, University of Ibadan, Nigeria
2Department of Chemical Sciences, Biochemistry Unit, College of Natural and Applied Sciences, Bells University of Technology Ota, Ogun State, Nigeria

Abstract

Stem bark extract of *Alstonia boonei* (SBEAB) was reported to possess anti-lipidemia, anti-microbial, anti-inflammatory and anti-hypercholesterolemia properties in folk lore medicine. The present study examined the effects of SBEAB on some key lipid profiles in diabetic induced rats. Biomarkers of lipid damage, histological and immunohistochemical method were used. The expression level of cyclooxygenase (COX-2) and inducible nitric oxide synthase (iNOS) were also determined. SBEAB administered orally at dose of 200 mg/kg for 14 days significantly lowered the levels of cholesterol, triglyceride and malondialdehyde induced by single intraperitoneal administration of streptozotoxin (STREP) (80 mg/kg) and preserved the integrity of intestinal villi. In addition, SBEAB reduced the STREP-induced elevated activity of CAT with concomitant repression of COX-2 and iNOS expression in the intestine of diabetic rats. The protective effect of SBEAB was compared to that of metaglomide (METAG), anti-diabetic drug. Pre and post-treatment are better to prevent pro-inflammatory response and intestinal cancer in diabetic rats than METAG-administration. Taken together, the inhibition of genes programming COX-2 and iNOS expression suggest the molecular mechanism for small intestinal tract protection by SBEAB and further advocates the links between the mal-absorption of cholesterol in diabetic patients.

Keywords: SBEAB; Anti-lipidemia; Anti-inflammatory; Diabetics; Rat

Introduction

High cholesterol level was recently discovered as a principal culprit behind various life threatening diseases like hypertension, cardiovascular diseases, atherosclerosis, obesity, hypercholesterolemia, metabolic syndrome, and even diabetes [1]. Cholesterol administration has been reported to influence hepatic lipid metabolism in mammals [2]. Hypercholesterolemia is usually characterized by both abnormal serum and hepatic triglyceride and cholesterol levels [2]. As such, increase serum total cholesterol caused impairment in the triglyceride metabolism leading to the accumulation/deposition of free fatty acids in the liver, thus triggering a condition known as fatty liver [2]. This expanded liver fatty acid pool leads to increased mitochondrial and pro-oxidant β-oxidation, which produces reactive oxygen species. This may, in turn, promote a local pro-inflammatory state leading to progressive liver injury [3,4].

Diabetes mellitus (DM) is one of the major causes of world morbidity and mortality and a common risk for cardiovascular diseases [5]. Previous study reported that diabetes mellitus is a metabolic disease characterized by hyperglycaemia resulting from defects in insulin secretion, insulin action, or both [6]. Complicated hyperglycaemia results from an absolute deficiency in insulin secretion (insulin-dependent diabetes mellitus or type 1 diabetes) [7]. Type-1 diabetes and type-2 diabetes share one essential feature: elevated blood sugar (glucose) levels. Based on the World Health Organization (WHO) report, the incidence of diabetes affects more than 170 million persons worldwide. It was recently projected that the total number of people with diabetes will reach 366 million by the year 2030 [8]. As the complication progresses, tissue or vascular damage ensues leading to severe diabetic complications such as retinopathy, neuropathy, nephropathy, cardiovascular complications and ulceration [9,10]. However, diabetes covers a wide range of heterogeneous diseases [11,12].

*Alstonia boonei* (apocynaceae) is a large perennial herb that grows abundantly in West Africa. It is commonly known as God’s tree, and used universally for its medicinal properties [13]. It contains several hundred valuable compounds and new constituents are still under investigation [13]. In traditional medicine, it is used as therapy against hypertension and several intestinal diseases with little scientific basis. Joseph et al. [14] and Fabiyi et al. [13] reported the anti-diabetic (hypoglycaemic) property of stool wood (God’s tree). It is also recommended by the traditional healers in West Africa for use as analgesic [15]. Therapeutically, the stem bark was found to possess anti-inflammatory, anti-oxidant and anti-inflammatory properties [15]. The extract from *Alstonia boonei* has also been reported to reduce the uptake of cholesterol from the gut [10,16].

Additionally, numbers of phytochemicals have been shown to inhibit COX-2 gene in vivo models of carcinogenesis [17]. Inducible nitric oxide synthase (iNOS) also causes the overproduction of nitric oxide during inflammation and tumorigenesis [18]. Hence, repression of the induction and activity of COX-2 and/or iNOS was regarded as novel concept in cancer prevention in many organs [19]. Although, several experimental studies have established the anti-diabetic effect

*Corresponding author: Akintunde Jacob Kehinde, Faculty of Public Health, Toxicology and Safety Unit, Department of Environmental Health Sciences, College of Medicine, University of Ibadan, Nigeria. Tel: +23408060415605; E-mail: akintundejacob@yahoo.com

Received November 05, 2016; Accepted November 18, 2016; Published November 25, 2016


Copyright: © 2016 Kehinde AJ, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
of many antioxidants [13,14,20]; but no significant study to the best of our knowledge had demonstrated the relationship between endo-
hypercholesterolemia and small intestinal inflammatory response in diabetic induced rats. Thus, the aim of the present study was to evaluate the effect of PUFAs from SBEAB on two key lipid profile (total cholesterol and triglyceride level), regulation of COX-2 and iNOS expression from STREP-induced diabetic rats.

Materials and Methods

Sample selection

Fresh sample of stem bark of *Alstonia boonei* was purchased from the local market, in Ota metropolis, Ogun State, Nigeria. Authentication of the plant was carried out in the Department of Biology, University of Ibadan, Nigeria. Adult male wistar strain albino rat was purchased from the Biochemistry Department animal colony, University of Ibadan, Nigeria and maintained *ad libitum* on commercial diet and water.

Chemicals and reagents

STREP was purchased from Sigma Chemical Co. (St Louis, MO, USA). Rabbit polyclonal COX-2 and iNOS antibodies were products of Cayman Chemical Co. (Ann Arbor, MI, USA). Bovine Serum Albumin (BSA), hydrogen peroxide, trichloroacetic acid (TCA) and thiobarbituric acid (TBA) were purchased from Sigma (St Louis, MO, USA). All the kits used for the bioassay were sourced from Randox Laboratories Ltd. (Crumlin, Dublin, Northern Ireland, UK). All other reagents used were in the purest form available commercially.

Extraction of stem bark *Alstonia boonei*

The bark of the stem was thoroughly washed in distilled water to remove any contaminant, chopped into small pieces before being milled. The ethanol extract of the stem was subsequently prepared by soaking the grinded sample (10 g) in ethanol (200 mL) for about 24 h at 37°C; the mixture was filtered and the filtrate was concentrated by rotator evaporator; designated as SBEAB and stored in the refrigerator at 37°C; the mixture was filtered and the filtrate was concentrated by rotator evaporator; designated as SBEAB and stored in the refrigerator for subsequent analysis.

Animal treatment

Adult male Wistar rats (200-300 g) from the Central Animal House of the Bells’ University of Technology, Ota, Nigeria were used in this experiment. The animals were maintained at a constant temperature of 22 ± 2°C on a 12 h light/dark cycle with free access to food and water. Animal care and handling was done according to the institutional guidelines of Nigeria Academy. The ethical conduct of research involving animals were follow.

Experimental protocol

The rats were acclimatized for two weeks and randomly divided into five groups of eight animals each (n=8). Group 1 (Control): serve as the normodiabetic control group; Group 2 (Induced): serve as the diabetics group induced with STREP plus NAD (STREP+NAD); Group 3 (STREP+METAG+NAD): serve as the positive control induced with STREP plus METAG (antidiabetic drug) plus NAD; Group 4 (Pre-treatment): serve as diabetic group pre-treated with 200 mg/kg body weight of *Alstonia boonei* extract (SBEAB before+NAD+STREP after) [21]; Group 5 (Post-treatment): serve as diabetic group post-treated with 200 mg/kg body weight of *Alstonia boonei* extract (SBEAB after+NAD+STREP before). 120 mg/kg body weight of nicotinamide (NAD), 80 mg/kg body weight of streptozotocin and 5 mg/kg body weight of metaglomide (METAG) were used. In the normodiabetic groups, the animals received water by gavage throughout the entire experiment to be subjected to the same stress (normodiabetic groups). The experiment lasted for two weeks (14 days).

Diabetic determination

The animals were subjected to overnight fast prior to the induction of diabetes. Streptozotocin (STREP) freshly prepared in citrate buffer (0.01 M, pH 4.5). Rats in groups 2,3,4 and 5 received a single intraperitoneal dose of STREP (80 mg/kg) for 72 hr [22]. Blood samples were taken by tail vein puncture and glucose levels was monitored using automatic auto-analyzer (Fine test Auto-coding™). Animals with blood glucose ≥ 200 mg/dl after 72 hr were considered diabetic and were used in the study. The non-diabetic animal received 1 ml of 0.1 M citrate buffer intraperitoneally. During the experiment, fasting blood glucose was monitored at 3 days interval. The blood was rapidly collected by direct heart puncture and the liver and testes were isolated, rinsed in cold saline (0.9%) and homogenized in phosphate buffer (pH 7.4). The protective effect of *Alstonia boonei* on STREP-induced diabetic was compared to that of metaglomide (5 mg/kg) which has been confirmed to have antidiabetic effects [20]. At the end of each experiment, rats were sacrificed by cervical dislocation. Blood was collected by heart puncture for serum isolation. Small intestine was excised, rinsed in physiological saline and stored at 4°C until use for histopathology and immunohistochemistry.

Measurement of cholesterol and triglyceride

The relevant lipid profiles; cholesterol and triglyceride were measured using commercially available kits (Randox Laboratories Kits, St Louis, MO, USA) according to the manufacturer’s guideline.

Determination of lipid peroxidation and catalase activity

Lipid peroxidation was assessed in terms of malondialdehyde (MDA) formation in the rat liver 10,000 g supernatant fractions. The measurement of thiobarbituric acid reacting substances (TBARS) was performed as described previously [23]. MDA was quantitated in nmole/mg protein. The estimation of catalase (CAT) activity using hydrogen peroxide as substrate was measured according to the method of Clairborne [24]. Protein concentration was determined by the method of Lowry et al. [25].

Histological study and immunohistochemical staining

Small intestine specimen was fixed in 10% neutral buffered formalin, embedded in paraffin, and sectioned. After deparaffinization and dehydration, the paraffin blocks were stained with hematoxylin and eosin for microscopic examination. For immunohistochemical analysis, the enzymatic activity of endogenous peroxidases in the liver section was first blocked with 3% hydrogen peroxide, followed by incubation with rabbit polyclonal anti rat COX-2 antibody (Cayman Chemical Co., Ann Arbor, MI, USA) at room temperature for 40 min. The peroxidase binding sites were detected by staining with 3, 3′-diaminobenzidine tetrahydrochloride (Dako, Glostrup, Denmark). Finally counterstaining was performed using Mayer's hematoxylin.

Statistical analysis

The data in each group were expressed as mean ± standard deviation. A one way analysis of variance (ANOVA) was used to analyze the results and Duncan multiple test was used for the post hoc [26]. Statistical package for Social Science (SPSS) 17.0 for windows was used for the analysis and the least significance difference (LSD) was accepted at P<0.05.
Results

The GC-MS spectrum of SBEAB contains 18 PUFAs with predominant occurrence of 1, 2-epoxyoctane, trans-2-nonenal, 1-(2-hydroxyl-1-nitroethyl) cyclohexanol and Spiro [1, 3-dioxolane-2, 2'-6(6, 7] diazobicyclo [3,2.2 non-6-ene (result not shown).

The protective effect of SBEAB on diabetic-induced intestinal injury was evaluated by determining the levels of MDA. As shown in Figure 1, SBEAB pre and post-treatment as well as metaglomide (anti-diabetic drug) significantly (P<0.05) lowered the level of MDA production in diabetic rats which indicate the end point of intestinal oxidative damage. In addition, there was a significant decrease in intestinal CAT activity of diabetic-induced rats (Figure 2). Histological examination of the small intestine also was in line with the above interpretation. Thus, small intestine specimens from diabetic rats showed inflammatory cellular aggregates in the cryptal regions with loss of some numbers of villi and their tips (Figures 3A and 3B) when compared with the control intestines (Figures 3C-3E). In metaglomide, SBEAB pre and post-treated rats, the cellular membrane of the villial cells was moderately not compromised (Figures 3C and 3E).

The cholesterol level, indicator of inducible hypercholesterolemia was significantly (p<0.05) higher in diabetic rats when compared with the control group (Figure 4). The remarkable hike level of cholesterol was extensively reduced by metaglomide, SBEAB pre and post-treatment in diabetic-induced animals (Figure 4). Similarly, the level of triglyceride (Figure 5) was significantly (p<0.05) increased in diabetic rats relative to control animals. The increased level of triglyceride was significantly (p<0.05) up-turned low after metaglomide, pre and post-treatment with SBEAB (Figure 5).

The protein expression of iNOS and COX-2 were evaluated in small intestine specimens from diabetic rats by immunohistochemistry. As shown in Figures 6 and 7 respectively, both proteins were highly expressed in diabetic rats when compared to the control. However, metaglomide, SBEAB pre and post-treatment decreased the expression of intestinal COX-2 and iNOS proteins in diabetic induced rats. The inhibition of COX-2 and iNOS expression in the small intestine of diabetic rats by SBEAB pre and post-treatment were efficacious than the reference anti diabetic drug-metaglomide (Table 1).

Discussion

The process of lipid peroxidation steals electrons from lipids in cell membrane causing unrestrained production of free radicals to initiate cell damage [27]. It usually affects polyunsaturated fatty acids, because they contain multiple double bonds in between the methylene -CH2- groups [28]. The present study revealed significant increase
and intestinal cancer [40]. In addition, molecular pathophysiological mechanism of hyperglycemia and hypercholesterolemia revealed alterations in lipid and amino acid metabolism [41]. However, the remarkable high level of cholesterol and triglycerides were considerably reversed by an anti-diabetic drug (metaglomide), SBEAB pre and post-treatment in diabetic-induced animals. The preventive mechanism of SBEAB pre-treatment was most efficacious in combating hypercholesterolemia in diabetic induced rats followed by SBEAB post-treatment and metaglomide respectively. This suggests that inhibition of cholesterol synthesis was responsible for the hypocholesterolemic effect by the combined PUFAs from stem bark extract of Alstonia boonei (SBEAB) in diabetic induced rat. Also, polyphenols are released at various points of the gastrointestinal tract (GIT) where they exert their beneficial effects [42]. Hypercholesterolemia in type-1 diabetes had been a major risk factor in the progression of cardiovascular diseases such as, atherosclerosis, myocardial infarction, heart attacks and cerebro-vascular diseases [39]. These disease conditions were implicated in death of people in many countries of the world [41]. And, lowering the plasma cholesterol levels has been demonstrated to reduce the risk of these diseases [38]. This further suggests that PUFAs from Alstonia boonei could improve the body cholesterol homeostasis. Pathologically, intestines from diabetic rats revealed inflammatory

in small intestinal MDA contents of diabetic induced rat. This result corroborates the previous investigations that patients that were diabetic had abnormal cell membrane [29] and high production of free radicals [30]. However, combined PUFAs from stem bark Alstonia boonei and anti-diabetic drug (METAG) caused a significant low production of MDA content in diabetic-induced rats. This is substantiated by recent studies that African herbs could modulate the oxidative damage in diabetic patients [31-33]. Also, the increased activity of CAT in diabetic animals was significantly ameliorated. This indicates that oxidative stress induced in diabetic rats was reversed by the presence of essential active compounds in the SBEAB. The reversal effect was supported by several findings in which administration of mixed PUFAs from crude extract in experimental animal model was reported as anti-diabetic agents [34,35].

In addition, studies have shown that phytochemicals such as PUFAs inhibit the activities of 3-hydroxyl-3-methylglutaryl CoA reductase (HMG-CoA reductase). This is the committed step in the cholesterol biosynthesis in the liver [36,37] and also intestinal acyl CoA; cholesterol acyltransferase (ACAT). These enzymes play a significant role in the absorption of cholesterol by esterification of cholesterol prior to absorption [37]. As observed from the present study, there was a significant rise in plasma cholesterol and triglyceride contents in diabetic induced rat. This observation agrees with previous studies where individuals suffering from type 1 diabetes depicted increased cholesterol and abnormal LDL-cholesterol level [38,39]. It was also reported that diabetic patients are more predisposed to colon

Figure 4: Effect of stem bark extract Alstonia boonei on cholesterol levels in diabetic-induced male rats. Data are presented as mean ± SD (n=8). Bars with different letters are statistically different.

Figure 5: Effect of stem bark extract Alstonia boonei on triglyceride level in diabetic-induced male rats. Data are presented as mean ± SD (n=8). Bars with different letters are statistically different.

Figure 6: Effect of dietary differential supplementation of Alstonia boonei on intestinal cyclooxygenase-2 (COX-2) expression in diabetic induced rats: (a) No visible expression of COX-2 (NVEC) i.e. the villi were intact and normal architectural structures of the membrane were observed. (b) Battered or eroded villi with distorted architectural structure of both membrane and internal parts in diabetic induced rats were seen, signifying the expression of COX-2 (SEC). (c) There was little expression of COX-2 (LEC) which resulted into mild distortion of the villi without distorted membrane architecture. (d) No visible expression of COX-2 (NVEG) i.e. there were intact and normal architectural structures of the membrane and the villi were not affected. (e) Also, this group showed no visible expression of COX-2 (NVEG). There were intact and normal architectural structures of the membrane and the villi were not affected.
villi are preponderantly manifested in diabetic patients than disease-affected small intestinal parts in diabetic induced rats were seen, signifying the expression of iNOS (NVEI). There were intact and normal architectural structures of the membrane were observed (b) Battered or eroded villi with distorted architectural structure of both membrane and intestinal cells in diabetic rats. (c) There was little expression of iNOS (LEI) which resulted into mild distortion of the villi without distorting membrane architecture (d) No visible expression of iNOS (NVEI) i.e. there were intact and normal architectural structures of the membrane and the villi were not affected. (e) Also, this group showed no visible expression of iNOS (NVEI). There were intact with normal architectural structures of the membrane and the villi were not affected.

Figure 7: Effect of differential treatment of Alstonia boonei on small intestinal inducible nitric oxide synthase (iNOS) expression in diabetic induced rats: (a) No visible expression of iNOS (NVEI) i.e. the villi were intact and normal architectural structures of the membrane were observed (b) Battered or eroded villi with distorted architectural structure of both membrane and internal parts in diabetic induced rats were seen, signifying the expression of iNOS (SEI). (c) There was little expression of iNOS (LEI) which resulted into mild distortion of the villi without distorting membrane architecture (d) No visible expression of iNOS (NVEI) i.e. there were intact and normal architectural structures of the membrane and the villi were not affected. (e) Also, this group showed no visible expression of iNOS (NVEI). There were intact with normal architectural structures of the membrane and the villi were not affected.

Table 1: Scoring of differential protective effect of stem bark extract Alstonia boonei and metaglomide on iNOS and COX-2 expression in small intestine of diabetic induced rats.

<table>
<thead>
<tr>
<th>Treatment</th>
<th>iNOS</th>
<th>COX-2</th>
</tr>
</thead>
<tbody>
<tr>
<td>Control</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Induced</td>
<td>2</td>
<td>2</td>
</tr>
<tr>
<td>Metaglomide</td>
<td>1</td>
<td>1</td>
</tr>
<tr>
<td>Pre-treatment</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>post-treatment</td>
<td>1</td>
<td>0</td>
</tr>
</tbody>
</table>

InOS, inducible nitric oxide synthase; COX-2, cyclooxygenase-2. Key to scores: 0=No intestinal cancer formation, 1=mild intestinal cancer formation, 2=severe intestinal cancer formation. Pre and post-treatment are more efficacious in preventing small intestinal cancer in diabetic rats than METAG-treatment (pre+post=METAG).

Conclusion

Essentially, PUFAs from Alstonia boonei depleted the level of plasma cholesterol and triglycerides with corresponding decrease in MDA levels of the small intestine in diabetic induced rat. The activity of enzymatic antioxidant- CAT was significantly elevated in diabetic induced rat; indicator of oxidative stress. The hike activity was reversed in animal group treated with SBEAB. Also, animals exposed to SBEAB showed reasonable preservation of the intestinal villi. Pre and post-treatment are better to prevent pro-inflammatory response and intestinal cancer in diabetic rats rather than METAG-administration. Taken together, the inhibition of genes encoding COX-2 and iNOS proteins suggest the molecular mechanism of the small intestine protection by SBEAB and further advocates the links between the malabsorption of cholesterol and diabetic individuals.

Compliance with Ethical Standards

All applicable international, national, and/or institutional guidelines for the care and use of animals were followed. This study was not funded by any organisation or institution that may influence the work.

Disclosure of Potential Conflict of Interest

Akintunde Jacob Kehinde declares that he has no conflict of interest. Ajiboye John Adebayo also declares that he has no conflict of interest. Soyinka Oluwadamilola equally declares that she has no conflict of interest. Similarly, Adeyemi Arinola declares that she has no conflict of interest.
Informed Consent

Informed consent was not applicable because the study did not involve human participants.

References


